FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	.C. 20549
---------------	-----------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Mackaness James H				2. Issuer Name and Ticker or Trading Symbol SOLENO THERAPEUTICS INC [SLNO]										ck all applic Directo Officer	able)	g Pers	son(s) to Iss 10% Ov Other (s	/ner	
(Last) 203 RED	,	irst) HORES PKWY,	(Middle) STE 500		3. Date of Earliest Transaction (Month/Day/Year) 03/31/2022									below) below) Chief Financial Officer					
(Street) REDWO CITY	REDWOOD CA 94065				4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date				2. Transa Date (Month/D	Execution Date,		Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and			5. Amour Securitie Beneficia Owned F Reported	s Form ally (D) o ollowing (I) (Ir		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) (D)	or F	Price	Transact (Instr. 3 a	ion(s)				
Common	Stock			03/31/	/2022		P		40,00	40,000 A		(1)	67,295			D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Di if any (Month/Day/	ate, Tr	ansacti ode (Ins	ion str.	of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transaction (Instr. 4)	i i ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Co	ode V	,	(A)		Date Exercisabl		xpiration ate	Title	or Nui of	mber ares					
Warrant (right to buy)	\$0.3	03/31/2022			P		40,000		03/31/202	2 0	3/31/2027	Common Stock	40	,000	(1)	40,000	0	D	

Explanation of Responses:

 $1. \ Each \ share \ of \ common \ stock \ was \ purchased \ together \ with \ one \ (1) \ warrant \ to \ purchase \ one \ (1) \ share \ of \ common \ stock \ for \ an \ aggregate \ price \ of \ \$0.25.$

Remarks:

/s/ James Mackaness

04/04/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.